These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11030021)

  • 1. FDA draws patients into alosetron risk management.
    Miller JL
    Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021
    [No Abstract]   [Full Text] [Related]  

  • 2. Alosetron use drops dramatically with risk management.
    Traynor K
    Am J Health Syst Pharm; 2004 Jun; 61(12):1210-2. PubMed ID: 15259746
    [No Abstract]   [Full Text] [Related]  

  • 3. Lotronex and the FDA: a fatal erosion of integrity.
    Horton R
    Lancet; 2001 May; 357(9268):1544-5. PubMed ID: 11377636
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
    Avigan M; Justice R; Mackey AC; Nair N
    Am J Gastroenterol; 2003 Sep; 98(9):2105-6. PubMed ID: 14499800
    [No Abstract]   [Full Text] [Related]  

  • 5. Return of alosetron.
    Hyman PE; Garvey TQ
    Expert Opin Drug Saf; 2002 May; 1(1):1-4. PubMed ID: 12904154
    [No Abstract]   [Full Text] [Related]  

  • 6. Alosetron to return to market.
    Young D
    Am J Health Syst Pharm; 2002 Jul; 59(14):1323-4. PubMed ID: 12132555
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA advisory panels recommend Lotronex be put back on market.
    Charatan F
    BMJ; 2002 May; 324(7345):1053. PubMed ID: 11993482
    [No Abstract]   [Full Text] [Related]  

  • 8. Glaxo Wellcome withdraws irritable bowel syndrome medication.
    FDA Consum; 2001; 35(1):3. PubMed ID: 11930921
    [No Abstract]   [Full Text] [Related]  

  • 9. Contemporary thoughts on the treatment of irritable bowel syndrome.
    Giaquinta D
    Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060
    [No Abstract]   [Full Text] [Related]  

  • 10. So what happened to alosetron?
    Hyams JS
    J Pediatr Gastroenterol Nutr; 2001 May; 32(5):513-4. PubMed ID: 11455947
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety concerns about alosetron.
    Camilleri M
    Arch Intern Med; 2002 Jan; 162(1):100-1. PubMed ID: 11784232
    [No Abstract]   [Full Text] [Related]  

  • 12. Alosetron: ischemic colitis and serious complications of constipation.
    Gallo-Torres H; Brinker A; Avigan M
    Am J Gastroenterol; 2006 May; 101(5):1080-3. PubMed ID: 16696787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irritable bowel syndrome. New treatment drug on the market.
    Harv Health Lett; 2000 Jun; 25(8):7. PubMed ID: 10810051
    [No Abstract]   [Full Text] [Related]  

  • 14. Possible mechanisms for ischemic colitis during alosetron therapy.
    Beck IT
    Gastroenterology; 2001 Jul; 121(1):231-2. PubMed ID: 11441889
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
    Chang L; Chey WD; Harris L; Olden K; Surawicz C; Schoenfeld P
    Am J Gastroenterol; 2006 May; 101(5):1069-79. PubMed ID: 16606352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alosetron: a case study in regulatory capture, or a victory for patients' rights?
    Moynihan R
    BMJ; 2002 Sep; 325(7364):592-5. PubMed ID: 12228140
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA advisers warn of more deaths if drug is relaunched.
    Moynihan R
    BMJ; 2002 Sep; 325(7364):561. PubMed ID: 12228121
    [No Abstract]   [Full Text] [Related]  

  • 18. Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?
    Shen B; Soffer EE
    Cleve Clin J Med; 2003 Jan; 70(1):64-5. PubMed ID: 12549728
    [No Abstract]   [Full Text] [Related]  

  • 19. Irritable bowel syndrome. A poorly understood disorder.
    Lewis C
    FDA Consum; 2001; 35(4):30-6. PubMed ID: 11692885
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel medications for the irritable bowel syndrome: motility and sensation.
    Camilleri M
    J Pediatr Gastroenterol Nutr; 2001; 32 Suppl 1():S35-7. PubMed ID: 11321419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.